Successful treatment of liver aspergilloma by caspofungin acetate first-line therapy in a non-immunocompromised patient.
Int J Mol Sci. 2012;13(9):11063-70
Authors: Bai QX, Huan Y, Wang JH, Yang LJ, Dong HJ
Aspergillosis remains to be a life-threatening complication in immunocompromised patients. However, Aspergillus infection can be observed in non-immunocompromised individuals in rare cases. We report a case of liver aspergilloma in a chronic aplastic anemia patient under relatively intact immune status. Therapeutic strategy for this rare condition was extensively discussed and caspofungin acetate single agent first-line therapy was applied after careful consideration. Encouraging clinical and radiologic improvements were achieved in response to the antifungal salvage. Our long-term follow-up study also revealed a favorable prognosis. Based on this experience, we suggest caspofungin acetate as first-line therapy for treatment plans of liver aspergilloma.
PMID: 23109838 [PubMed]